2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kamar, N. Articles by Rostaing, L. Search for Related Content PubMed PubMed Citation Articles by Kamar, N. Articles by Rostaing, L.

Evidence that Clearance of Hepatitis C Virus RNA after -Interferon Therapy in Dialysis Patients Is Sustained after Renal Transplantation

Nassim Kamar^*, Olivier Toupance, Matthias Buchler, Karine Sandres-Saune, Jacques Izopet, Dominique Durand^* and Lionel Rostaing^*

*Department of Nephrology, Dialysis and Transplantation, CHU Rangueil, Toulouse, Department of Virology, CHU Purpan, Toulouse, Department of Nephrology, CHU Reims, Maison Blanche Hospital, Reims, and Department of Nephrology, CHU Tours, Bretonneau Hospital, Tours, France.

Correspondence to Dr. L. Rostaing, Department of Nephrology, Dialysis and Transplantation, CHU Rangueil, 1 avenue jean Poulhès, 31403 Toulouse Cedex 4, France. Phone: +33 5 61 32 26 84; Fax: +33 5 61 32 28 64;

ABSTRACT. To date, there is no available treatment of hepatitis C virus (HCV) infection after renal transplantation (RT). Among 55 anti-HCV–positive/HCV RNA–positive hemodialysis patients who were treated with IFN- (9 MU/wk during 6 or 12 mo), 21 of them (38%) had a sustained virologic response. Of these, 16 (76%) underwent RT 38 mo (range, 2 to 57 mo) after -IFN therapy. There were 13 men and 3 women aged 46 yr (range, 27 to 68 yr). At RT, HCV serology was still positive in 15 patients, and HCV viremia was negative in all patients. Immunosuppression relied on anticalcineurin agents with or without steroids and/or antimetabolites; in addition, 12 of them received induction therapy with antithymocyte globulins. At the last follow-up after RT, at 22.5 mo (range, 2 to 88 mo), HCV viremia remained negative in all patients. Moreover, HCV RNA was not present in peripheral blood mononuclear cells when assessed in eight patients. HCV serology was found to be still positive in 13 patients. Three patients presented with acute rejection, one presented with a suppurative lymphocele, one died from a sepsis, and four presented with a cytomegalovirus infection. None of them developed posttransplant diabetes mellitus. In conclusion, hemodialysis patients waiting for a RT need to be treated with -IFN because when HCV RNA clearance occurred, they experienced no relapse after transplantation despite chronic immunosuppressive treatment. E-mail: rostaing.l@chu-toulouse.fr

This article has been cited by other articles:

				H. Weclawiack, N. Kamar, M. Mehrenberger, C. Guilbeau-Frugier, A. Modesto, J. Izopet, D. Ribes, F. Sallusto, and L. Rostaing Alpha-interferon therapy for chronic hepatitis C may induce acute allograft rejection in kidney transplant patients with failed allografts Nephrol. Dial. Transplant., March 1, 2008; 23(3): 1043 - 1047. [Abstract] [Full Text] [PDF]

				R. D. Bloom and M. F. Crutchlow New-Onset Diabetes Mellitus in the Kidney Recipient: Diagnosis and Management Strategies Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(Supplement_2): S38 - S48. [Abstract] [Full Text] [PDF]

				R. van Leusen, R. P. R. Adang, R. A. de Vries, T. T. Cnossen, C. J. A. M. Konings, S. W. Schalm, and A. C. I. T. L. Tan Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C Nephrol. Dial. Transplant., February 1, 2008; 23(2): 721 - 725. [Abstract] [Full Text] [PDF]

				N. A. Terrault and D. B. Adey The Kidney Transplant Recipient with Hepatitis C Infection: Pre- and Posttransplantation Treatment Clin. J. Am. Soc. Nephrol., May 1, 2007; 2(3): 563 - 575. [Abstract] [Full Text] [PDF]

				M. F. Crutchlow and R. D. Bloom Transplant-Associated Hyperglycemia: A New Look at an Old Problem Clin. J. Am. Soc. Nephrol., March 1, 2007; 2(2): 343 - 355. [Abstract] [Full Text] [PDF]

				F. Fabrizi, G. Lunghi, F. Aucella, S. Mangano, F. Barbisoni, S. Bisegna, D. Vigilante, A. Limido, and P. Martin Novel Assay Using Total Hepatitis C Virus (HCV) Core Antigen quantification for Diagnosis of HCV Infection in Dialysis Patients J. Clin. Microbiol., January 1, 2005; 43(1): 414 - 420. [Abstract] [Full Text] [PDF]

				Z. T. Bloomgarden Transplantation and Islet Topics Diabetes Care, January 1, 2005; 28(1): 213 - 219. [Full Text] [PDF]

				T. Fehr and P. M. Ambuhl Chronic hepatitis virus infections in patients on renal replacement therapy Nephrol. Dial. Transplant., May 1, 2004; 19(5): 1049 - 1053. [Full Text] [PDF]

				S. Zeuzem Heterogeneous Virologic Response Rates to Interferon-Based Therapy in Patients with Chronic Hepatitis C: Who Responds Less Well? Ann Intern Med, March 2, 2004; 140(5): 370 - 381. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673